)
Visual6 Mar 2026
Reddit's DAUq growth
Foghorn Therapeutics
Foghorn Therapeutics (FHTX) investor relations material
Foghorn Therapeutics TD Cowen 46th Annual Health Care Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.TD Cowen 46th Annual Health Care Conference summary3 Mar, 2026
Strategic partnerships and pipeline overview
Partnership with Eli Lilly includes a 50/50 collaboration on the SMARCA2 program, with additional targets under Lilly's rights and a significant oncology deal established in December 2021.
Proprietary pipeline features selective CBP, EP300, and ARID1B degrader programs, with IND-enabling studies for CBP and EP300 expected later this year and in vivo proof of concept for ARID1B targeted for 2026.
An I&I program with a novel target is projected for IND in 2027, pending continued validation.
The company is advancing induced proximity approaches, with more developments anticipated over the next year.
Recent $50 million direct offering extends financial runway by approximately two quarters at current burn rate.
Clinical progress and trial updates
SMARCA2 program is in dose escalation, with no maximum tolerated dose reached; sites are open in the US, Japan, France, Germany, Spain, and South Korea.
Backfilling of cohorts began in Q4, focusing on non-small cell lung cancer patients with strong loss-of-function SMARCA4 mutations.
Decision on dose expansion is expected around mid-year, depending on ongoing phase 1 results.
Enrollment has been efficient due to proactive site openings, facilitating seamless transition to expansion if warranted.
Safety and tolerability have been favorable, with no dose-limiting toxicities reported to date.
Scientific and clinical rationale
Chromatin regulatory system mutations are prevalent in oncology and other diseases, with selective drugging achieved after years of effort.
SMARCA4-mutant non-small cell lung cancer patients have poor prognosis, especially when co-mutated with KRAS, highlighting high unmet need.
Combination strategies with KRAS inhibitors are anticipated in future expansion phases.
CBP and EP300 degraders show promising preclinical efficacy and improved safety profiles compared to dual bromodomain inhibitors.
ARID1B degrader program is progressing, with selective degradation achieved and in vivo proof of concept targeted for 2026.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Next Foghorn Therapeutics earnings date
Q4 202513 Mar, 2026
Foghorn Therapeutics
Next Foghorn Therapeutics earnings date
Q4 202513 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of novel therapies targeting the chromatin regulatory system, which plays a critical role in gene expression and cellular identity. The company leverages its proprietary Gene Traffic Control platform to gain an integrated understanding of how chromatin regulation affects disease, enabling it to identify and develop potential drug candidates. Foghorn's research focuses on treating genetically determined dependencies in various cancers, including hematologic malignancies and solid tumors. The company has collaborations with major pharmaceutical firms to further its therapeutic pipeline. Foghorn Therapeutics is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage